company background image
OPT

Opthea ASX:OPT Stock Report

Last Price

AU$1.38

Market Cap

AU$478.9m

7D

5.3%

1Y

11.3%

Updated

09 Aug, 2022

Data

Company Financials +
OPT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

OPT Stock Overview

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia.

Opthea Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Opthea
Historical stock prices
Current Share PriceAU$1.38
52 Week HighAU$1.48
52 Week LowAU$0.79
Beta0.35
1 Month Change20.52%
3 Month Change14.52%
1 Year Change11.29%
3 Year Change-46.92%
5 Year Change66.27%
Change since IPO2,200.00%

Recent News & Updates

Jul 21
Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

OPTAU BiotechsAU Market
7D5.3%0.1%0.7%
1Y11.3%-1.3%-8.0%

Return vs Industry: OPT exceeded the Australian Biotechs industry which returned -1.3% over the past year.

Return vs Market: OPT exceeded the Australian Market which returned -8% over the past year.

Price Volatility

Is OPT's price volatile compared to industry and market?
OPT volatility
OPT Average Weekly Movement9.1%
Biotechs Industry Average Movement11.7%
Market Average Movement10.5%
10% most volatile stocks in AU Market17.6%
10% least volatile stocks in AU Market4.6%

Stable Share Price: OPT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: OPT's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1984n/aMegan Baldwinhttps://www.opthea.com

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company’s development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases.

Opthea Limited Fundamentals Summary

How do Opthea's earnings and revenue compare to its market cap?
OPT fundamental statistics
Market CapUS$335.24m
Earnings (TTM)-US$57.33m
Revenue (TTM)n/a

9,999x

P/S Ratio

-5.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OPT income statement (TTM)
Revenue-US$11.06k
Cost of RevenueUS$392.58k
Gross Profit-US$403.64k
Other ExpensesUS$56.92m
Earnings-US$57.33m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin3,649.90%
Net Profit Margin518,374.03%
Debt/Equity Ratio0%

How did OPT perform over the long term?

See historical performance and comparison